Vermillion Q2 Revenues Dip 9 Percent

The drop-off resulted from a decrease in license revenues related to milestone payments from Quest Diagnostics for the OVA test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories